Navigation Links
AEterna Zentaris Announces the Departure of SVP, Administrative and Legal Affairs
Date:2/29/2008

QUEBEC CITY, Feb. 29 /PRNewswire-FirstCall/ - AEterna Zentaris Inc. (NASDAQ: AEZS; TSX: AEZ), a global biopharmaceutical company focused on endocrine therapy and oncology, today announced the resignation of Mario Paradis, CA, the Company's Senior Vice President, Administrative & Legal Affairs and Corporate Secretary. Mr. Paradis has accepted the position of Vice President and Chief Financial Officer of Atrium Innovations, a leading developer, manufacturer and marketer of science-based products for the cosmetics, pharmaceutical, chemical and nutrition industries. Mr. Paradis will remain in his capacity at the Company through a transition period, and his departure will become effective in early April.

David J. Mazzo, Ph.D., President and CEO of AEterna Zentaris commented, "We would like to extend our sincere appreciation to Mario for his dedication and significant contributions to the evolution of AEterna Zentaris over the years. We wish him well as he embarks on this new chapter in his career."

About AEterna Zentaris Inc.

AEterna Zentaris Inc. is a global biopharmaceutical company focused on endocrine therapy and oncology with proven expertise in drug discovery, development and commercialization.
News releases and additional information are available at http://www.aezsinc.com.

Forward-Looking Statements

This press release contains forward-looking statements made pursuant to the safe harbor provisions of the U.S. Securities Litigation Reform Act of 1995. Forward-looking statements involve known and unknown risks and uncertainties, which could cause the Company's actual results to differ materially from those in the forward-looking statements. Such risks and uncertainties include, among others, the availability of funds and resources to pursue R&D projects, the successful and timely completion of clinical studies, the ability of the Company to take advantage of business opportunities in the pharmaceutical industry, uncertainties related to the regulatory process and general changes in economic conditions. Investors should consult the Company's quarterly and annual filings with the Canadian and U.S. securities commissions for additional information on risks and uncertainties relating to the forward-looking statements. Investors are cautioned not to rely on these forward-looking statements. The Company does not undertake to update these forward-looking statements. We disclaim any obligation to update any such factors or to publicly announce the result of any revisions to any of the forward-looking statements contained herein to reflect future results, events or developments except if we are requested by a governmental authority or applicable law.


'/>"/>
SOURCE AETERNA ZENTARIS INC.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Aeterna Zentaris to Announce Fourth Quarter and Full-Year 2007 Financial and Operating Results on March 5, 2008
2. AEterna Zentaris to Present at the Upcoming Roth Capital Partners 20th Annual OC Growth Stock Conference in Dana Point, California
3. AEterna Zentaris Reports First Patients Treated with Anti-Cancer Compound AEZS-108 in Phase 2 Trial in Ovarian and Endometrial Cancers
4. AEterna Zentaris to Further Develop Three Follow-up Multi-targeted Cytotoxic Candidates to AEZS-112 as Potential Novel Cancer Treatment
5. AEterna Zentaris Announces Outcome of Managements Strategic Review
6. AEterna Zentaris to Present at Upcoming UBS Global Life Sciences Conference in New York
7. AEterna Zentaris completes management team with the appointment of Chief Medical Officer
8. Exelixis Announces March 4 Webcast of Presentation at the Susquehanna SIGnificant Options in Healthcare Conference
9. MarketResearch.com Announces Distribution of Spectra Intelligence Research
10. Kosan Announces Senior Management Changes and Clinical Portfolio Priorities
11. Kosan Announces Fourth Quarter and Full Year 2007 Financial Results and 2008 Outlook
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... June 28, 2017 (PRWEB) , ... ... ... latest release of Siemens’ STAR-CCM+® software for multiphysics computational fluid dynamics (CFD) ... product design exploration and optimization. STAR-CCM+ version 12.04 introduces Design Manager, allowing ...
(Date:6/27/2017)... ... 2017 , ... Brain State Technologies, a leading neurotechnology company, ... 15th to fund production of the new B2v2 wearable brainwave balancing headband. Over ... more than 150% in a little over a week. , Utilizing Brain State’s ...
(Date:6/27/2017)... Iowa (PRWEB) , ... June 27, 2017 , ... ... technology license agreement whereby DuPont gains exclusive rights to the ERS patent portfolio ... ERS was formed to commercialize the foundational intellectual property (IP) of the CRISPR-Cas ...
(Date:6/26/2017)... ... June 26, 2017 , ... Two new members were elected to ... June 9, 2017: Jeremy Nowak, President, J Nowak Strategy and Michele Masucci, Ph.D., Vice ... election of Glen N. Gaulton and Kenneth L. Kring, and re-election of David P. ...
Breaking Biology Technology:
(Date:5/16/2017)...  Veratad Technologies, LLC ( www.veratad.com ), an innovative ... verification solutions, announced today they will participate as a ... thru May 17, 2017, in Washington D.C.,s ... Identity impacts the lives of billions ... evolving digital world, defining identity is critical to nearly ...
(Date:5/6/2017)... May 5, 2017 RAM Group ... a new breakthrough in biometric authentication based on ... mechanical properties to perform biometric authentication. These new sensors ... material created by Ram Group and its partners. This ... transportation, supply chains and security. Ram Group is ...
(Date:4/19/2017)... ALBANY, New York , April 19, 2017 /PRNewswire/ ... highly competitive, as its vendor landscape is marked by ... in the market is however held by five major ... and Safran. Together these companies accounted for nearly 61% ... majority of the leading companies in the global military ...
Breaking Biology News(10 mins):